Clinical trials: Malignant Melanomas
Brain Neoplasms, Neoplasm Metastasis
Surgery Versus Radiosurgery to Treat Metastatic Brain Tumors
This study will compare the effectiveness of craniotomy to that of stereotactic surgery (SRS) for the treatment of metastatic brain tumors - tumors that first develop elsewhere in the body and then travel to the brain.
- Trial name
- NCT00075166
- Testing
- Stereotactic surgery (SRS), Craniotomy
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
The purpose of this first in human (FIH) trial was to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and identify a recommended dose for future studies in…
- Conditions
- Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal Squamous Cell Cancer (SCC), Head/Neck SCC
- Trial name
- NCT03114319
- Testing
- TNO155, TNO155 in combination with EGF816 (nazartinib)
- Where
- 18 sites in United States, Canada and 7 more
- Volunteers
- 227 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumors
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
The purpose of this study is to assess the safety and antitumor activity of INCB001158 plus epacadostat, with or without pembrolizumab, in participants with advanced or metastatic solid tumors.
- Trial name
- NCT03361228
- Testing
- INCB001158, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Incyte Corporation
Malignant Melanoma, Cancer
Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies
The purpose of this study is to characterize the pharmacokinetics (PK) of a single intravenous (IV) infusion of 14C-labeled vemurafenib administered shortly after an oral dose of vemurafenib and following multiple oral doses of…
- Trial name
- NCT02441465
- Testing
- Vemurafenib, 14C-Labeled Vemurafenib
- Where
- Hungary
- Volunteers
- 6 people
- Sponsor
- Hoffmann-La Roche
Melanoma Stage IV, Melanoma Stage III
Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment
BERING-MELANOMA - designed as a prospective, longitudinal, non-interventional study - investigates real-world effectiveness, quality of life, safety and tolerability of encorafenib plus binimetinib in unresectable advanced or…
- Trial name
- BERING (NCT04045691)
- Testing
- Encorafenib, Binimetinib
- Where
- 59 sites in Austria, Germany and 1 more
- Volunteers
- 750 people
- Sponsor
- Pierre Fabre Pharma GmbH
Melanoma
A Clinical Trial of Patients With Melanoma
This study is being done to find out if the combination of dabrafenib, trametinib and digoxin will lessen the side effects that you may experience and to measure your response and duration of response to the combination of drugs.
- Trial name
- NCT02915666
- Testing
- Digoxin Combination, Dabrafenib, Trametinib
- Where
- United States
- Sponsor
- University of Texas Southwestern Medical Center
Melanoma
A Phase I-c Study of Recombinant GM-CSF Herpes Simplex Virus to TreatⅣ M1c
Recombinant human GM-CSF herpes simplex virus injection (OrienX010) is a genetically engineered from Chinese patients oral separation of wild type 1 herpes simplex virus (HSV) as the carrier insert GM-CSF gene therapy drug.After…
- Trial name
- NCT03048253
- Testing
- OrienX010
- Where
- China
- Volunteers
- 30 people
- Sponsor
- OrienGene Biotechnology Ltd.
Melanoma, Neuroblastoma
PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study
The purpose of this study is to find out how an antibody called Hu3F8 travels through the body and to tumors. Antibodies, like Hu3F8, are proteins that help attack tumors or fight infections.
- Conditions
- Melanoma, Neuroblastoma, Sarcoma
- Trial name
- NCT02307630
- Testing
- 124I-Humanized 3F8
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma
Interest of Tumor Replicates in Avian Embryo to Model Therapeutic Effects of BRAFi/MEKi in BRAF Mutated Melanoma
This is an interventional mono-centric study in patients with BRAF mutated metastatic melanoma treated with BRAF/MEK inhibitors.
- Trial name
- MELANOPREDICT (NCT04039672)
- Testing
- Skin biopsy
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Hospices Civils de Lyon
Breast Cancer, Genitourinary Cancer
Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass
The goal of this clinical research study is to measure the amount of inflammatory proteins inside the body before and after lymphatico-venular bypass surgery.
- Conditions
- Breast Cancer, Genitourinary Cancer, Malignant Female Reproductive System Neoplasm, Melanoma
- Trial name
- NCT01433302
- Testing
- Punch Biopsy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Melanoma, Stage IV Melanoma
Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery
This randomized phase II trial is studying how well giving sorafenib together with either temsirolimus or tipifarnib works in treating patients with stage IV melanoma that cannot be removed by surgery.
- Trial name
- NCT00281957
- Testing
- sorafenib tosylate, tipifarnib, temsirolimus
- Where
- 173 sites in United States
- Volunteers
- 109 people
- Sponsor
- National Cancer Institute (NCI)
Intraocular Melanoma, Melanoma (Skin)
Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response that will kill tumor cells. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating white blood…
- Trial name
- NCT00003339
- Testing
- gp100 antigen, incomplete Freund's adjuvant, recombinant interleukin-12
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- University of Southern California
Melanoma
Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma
In 2014, an estimated 7,000 patients were diagnosed of melanoma in China. It is growing at an annual rate of 3%-5% and approximately 20,000 new cases are reported each year recently.To date, CFDA only approved dacarbazine as…
- Trial name
- NCT05104801
- Testing
- sitravatinib, tislelizumab
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Peking University Cancer Hospital & Institute
Melanoma, Acral Melanoma
Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma
Neoadjuvant therapy is feasible in stage Ⅱ-Ⅲ melanoma, Carrelizumab combined with apatinib and temozolomide has synergistic antitumor effects and may improve pathological response.
- Conditions
- Melanoma, Acral Melanoma, Temozolomide, Apatinib
- Trial name
- NCT05512481
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Cancer Hospital & Institute
Metastatic Melanoma
Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients
This is a Phase 2 trial consisting of 24 patients receiving the combination of dabrafenib + trametinib + pembrolizumab in 3 different dosing schemes and 8 patients receiving pembrolizumab standard monotherapy.
- Trial name
- IMPemBra (NCT02625337)
- Testing
- Pembrolizumab, Dabrafenib, Trametinib
- Where
- Netherlands
- Volunteers
- 32 people
- Sponsor
- The Netherlands Cancer Institute
Advanced Melanoma, Metastatic Melanoma
Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma
This is a multi-center, open-label, phase 2 study evaluating the humanized anti-PD-1 antibody JS001, as a monotherapy in patients with locally advanced or metastatic melanoma who have failed in routine systemic treatment.
- Trial name
- NCT03013101
- Testing
- humanized anti-PD-1 monoclonal antibody toripalimab
- Where
- 6 sites in China
- Volunteers
- 128 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Melanoma (Skin)
Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery
RATIONALE: Studying samples of blood, tumor tissue, and skin in the laboratory from patients with melanoma receiving hydroxychloroquine may help doctors understand the effect of hydroxychloroquine on biomarkers.
- Trial name
- NCT00962845
- Testing
- hydroxychloroquine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Rutgers, The State University of New Jersey
Malignant Melanoma
A Study of Toripalimab or Combining With Temozolomide（iv） in the Treatment of Advanced/Metastatic Malignant Melanoma
This study evaluate toripalimab or combining with temozolomide for injection in the treatment of advanced/metastatic malignant melanoma. Participants in arm A receive toripalimab, in arm B receive toripalimab plus temozolomide
- Trial name
- NCT04884997
- Testing
- toripalimab, Temozolomide Injection
- Where
- China
- Volunteers
- 90 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Melanoma, Quality of Life
Quality of Life and Surgical Late Effects of Melanoma Treatment
Health-related Quality of life in Danish stage IB-III cutaneous melanoma patients.
- Conditions
- Melanoma, Quality of Life, Lymphedema, Depression
- Trial name
- NCT02352623
- Testing
- DXA scan, Clinical examination
- Where
- Denmark
- Volunteers
- 435 people
- Sponsor
- Herlev Hospital
Melanoma (Skin)
Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Interleukin-2 and sargramostim may stimulate a person's white blood cells to kill melanoma cells. PURPOSE: This phase II trial is studying how well giving interleukin-2 together with sargramostim works in treating…
- Trial name
- NCT00085579
- Testing
- aldesleukin, sargramostim, adjuvant therapy
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.